Bristol-Myers, Clovis leap into PhIII combo studies in a PD-1/PARP play as rivals circle
The checkpoint combo deal frenzy continues this morning with a tie-up between Bristol-Myers Squibb and Clovis that will marry their PD-1/PARP drugs and leap straight …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
